T Xu1, G Liang2, L Yang3, F Zhang3. 1. Department of Respiratory Medicine, Tianjin Hospital of ITCWM, Nankai Hospital, Sanwei Road, Nankai District, Tianjin, 300100, China. xtbyln@163.com. 2. Department of International Medical Center, Tianjin First Center Hospital, Fukang Road, Tianjin, 300192, China. 3. Department of Respiratory Medicine, Tianjin Hospital of ITCWM, Nankai Hospital, Sanwei Road, Nankai District, Tianjin, 300100, China.
Abstract
BACKGROUNDS: It has been reported that metformin has an anticancer impact in various solid tumors, but its role in small cell lung cancer (SCLC) remains unclear. This study aimed to investigate the effect of metformin on survival in diabetic SCLC patients. METHODS: A total of 79 SCLC patients with diabetes treated in our hospital between 2000 and 2010 were enrolled. The clinicopathological data and survival time were collected and evaluated. Univariate and multivariate analyses were used to investigate the association between metformin use and the survival of SCLC. RESULTS: Among the 79 diabetic patients, 36 patients took metformin. The median OS and DFS were significantly better in the metformin group compared to non-metformin group (OS 18.0 vs 11.5 months, p < 0.001; DFS 10.8 vs 6.5 months, p < 0.001). Multivariate Cox analysis indicated that metformin use was an independent prognostic factor for long-term outcome (HR = 0.549, 95 % CI 0.198-0.978, p = 0.001). CONCLUSIONS: The prognosis of SCLC patients with diabetes treated with metformin was improved, which might be considered a potential useful anticancer drug in treating SCLC patients.
BACKGROUNDS: It has been reported that metformin has an anticancer impact in various solid tumors, but its role in small cell lung cancer (SCLC) remains unclear. This study aimed to investigate the effect of metformin on survival in diabetic SCLCpatients. METHODS: A total of 79 SCLCpatients with diabetes treated in our hospital between 2000 and 2010 were enrolled. The clinicopathological data and survival time were collected and evaluated. Univariate and multivariate analyses were used to investigate the association between metformin use and the survival of SCLC. RESULTS: Among the 79 diabeticpatients, 36 patients took metformin. The median OS and DFS were significantly better in the metformin group compared to non-metformin group (OS 18.0 vs 11.5 months, p < 0.001; DFS 10.8 vs 6.5 months, p < 0.001). Multivariate Cox analysis indicated that metformin use was an independent prognostic factor for long-term outcome (HR = 0.549, 95 % CI 0.198-0.978, p = 0.001). CONCLUSIONS: The prognosis of SCLCpatients with diabetes treated with metformin was improved, which might be considered a potential useful anticancer drug in treating SCLCpatients.
Entities:
Keywords:
Diabetes; Metformin; Prognosis; Small cell lung cancer
Authors: Soley Bayraktar; Leonel F Hernadez-Aya; Xiudong Lei; Funda Meric-Bernstam; Jennifer K Litton; Limin Hsu; Gabriel N Hortobagyi; Ana M Gonzalez-Angulo Journal: Cancer Date: 2011-07-28 Impact factor: 6.860
Authors: Jenny J Lin; Emily J Gallagher; Keith Sigel; Grace Mhango; Matthew D Galsky; Cardinale B Smith; Derek LeRoith; Juan P Wisnivesky Journal: Am J Respir Crit Care Med Date: 2015-02-15 Impact factor: 21.405
Authors: Craig J Currie; Chris D Poole; Sara Jenkins-Jones; Edwin A M Gale; Jeffrey A Johnson; Christopher Ll Morgan Journal: Diabetes Care Date: 2012-01-20 Impact factor: 19.112
Authors: Suzan Brancher; Nathalie C Støer; Elisabete Weiderpass; Ronald A M Damhuis; Tom B Johannesen; Edoardo Botteri; Trond-Eirik Strand Journal: Br J Cancer Date: 2020-12-02 Impact factor: 7.640